Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ekso Bionics Holdings's revenue for the
three
months ended in Mar. 2026 was $2.14 Mil.
Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was $11.57 Mil.
Ekso Bionics Holdings's Revenue per Share for the
three
months ended in Mar. 2026 was $0.60.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $4.14.
Warning Sign:
Ekso Bionics Holdings Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Ekso Bionics Holdings was -66.10% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -29.30% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -16.00% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -25.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, Ekso Bionics Holdings's highest 3-Year average Revenue per Share Growth Rate was 2.10% per year. The lowest was -36.70% per year. And the median was -29.30% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Ekso Bionics Holdings's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ekso Bionics Holdings Revenue vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Ekso Bionics Holdings's Revenue distribution charts can be found below:
* The bar in red indicates where Ekso Bionics Holdings's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $11.57 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ekso Bionics Holdings (EKSO) has a Revenue of $11.57 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Ekso Bionics Holdings and its competitors.
Is Ekso Bionics Holdings' Revenue too high?
Ekso Bionics Holdings' current Revenue is $11.57 Mil. Overall, Ekso Bionics Holdings has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Ekso Bionics Holdings' Revenue compare to POCI and HBIO?
Ekso Bionics Holdings' Revenue of $11.57 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Medical Devices & Instruments company?
A good Revenue depends on the Medical Devices & Instruments industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Ekso Bionics Holdings and its competitors. Ekso Bionics Holdings's current Revenue is $11.57 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ekso Bionics Holdings stock overvalued right now?
Ekso Bionics Holdings (EKSO) has a current Revenue of $11.57 Mil. The stock's GF Value™ is $4.40, compared to a current price of $11.65 — trading 164.8% above its estimated fair value. The current Revenue is $11.57 Mil. Ekso Bionics Holdings' overall GF Score™ is 32/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Ekso Bionics Holdings (EKSO), the current Revenue is $11.57 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ekso Bionics Holdings (EKSO) Overvalued in 2026?
Based on GuruFocus' analysis, Ekso Bionics Holdings stock appears to be overvalued.
The current stock price of $11.65 is trading 164.8% above its estimated GF Value™ of $4.40.
Key valuation signals for EKSO:
Revenue: $11.57 Mil
GF Value™: $4.40 vs. price of $11.65 (164.8% above fair value)
No single metric tells the full story. See the EKSO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ekso Bionics Holdings Inc designs, develops and sells exoskeleton technology used in healthcare and industrial markets. The wearable exoskeletons are to be worn over clothes and controlled by a trained operator to augment human strength, endurance, and mobility. The company's segments are Enterprise Health and Personal Health. All of the company's operations are held in the United States. The regions the company operates in are the Americas, EMEA, and APAC.
32GF Score
Get the complete analysis for EKSO
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EKSO has been successfully added to your 
